Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

3003 - Evaluation of hypertension and hand-foot syndrome as Markers of anlotinib Efficacy in advanced soft tissue sarcoma

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Targeted Therapy

Tumour Site

Soft Tissue Sarcomas

Presenters

Zhiwei Fang

Citation

Annals of Oncology (2018) 29 (suppl_8): viii576-viii595. 10.1093/annonc/mdy299

Authors

Z. Fang1, Y. Chi2, Y. Yao3, S. Wang4, G. Huang5, Q. Cai6, G. Shang7, G. Wang8, G. Qu9, Q. Wu10, Y. Jiang11, J. Song12, J. Chen13, X. Zhu14, Z. Cai15, C. Bai16, Y. Lu17, Z. Yu18, J. Shen19, J. Cai2

Author affiliations

  • 1 Bone And Soft Tissue Tumors, Peking University Cancer Hospital, 100142 - Beijing/CN
  • 2 Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CAMS), 100021 - Beijing/CN
  • 3 Medical Oncology, Affiliated Sixth People’s Hospital, Shanghai Jiaotong University, 200233 - Shanghai/CN
  • 4 Oncology, Cancer Centre Sun Yat-Sen University, 510060 - Guangzhou/CN
  • 5 Oncology, Hunan Cancer Hospital, 410006 - Changsha/CN
  • 6 Bone, Henan Cancer Hospital, 450008 - Zhengzhou/CN
  • 7 Bone, Liaoning Cancer Hospital and Institute, 110042 - Shenyang/CN
  • 8 Bone, Tianjin Medical University Cancer Institute and Hospital, 300000 - Tianjin/CN
  • 9 Bone, Harbin Medical University Cancer Hospital, 150000 - Harbin/CN
  • 10 Bone, The first Affiliated Hospital of Bengbu Medical College, 233000 - Bengbu/CN
  • 11 Oncology, West China Hospital, 610041 - Chengdu/CN
  • 12 Bone, Gansu Provincial Cancer Hospital, 730000 - Lanzhou/CN
  • 13 Bone, Wuhan Union Hospital (of Tongji Medical College of HUST), 430022 - Wuhan/CN
  • 14 Oncology, The first Affiliated Hospital of Fujian Medical University, 350000 - Fuzhou/CN
  • 15 Bone, Shanghai General Hospital, 200000 - Shanghai/CN
  • 16 Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100730 - Beijing/CN
  • 17 Oncology, The Affiliated Tumor Hospital of Guangxi Medical University, 530000 - Nanning/CN
  • 18 Oncology, Jiangxi Cancer Hospital, 330000 - Nanchang/CN
  • 19 Bone, The First Affiliated Hospital of Sun Yat-sen University, 510000 - Guangzhou/CN
More

Resources

Abstract 3003

Background

ALTER0203 was a randomized phase IIB trial (NCT02449343) that demonstrated single-agent activity of anlotinib in advanced STS (aSTS). The primary endpoint progression-free survival (PFS) was met and presented as an oral presentation in 2018 ASCO. Similar to other vascular endothelial growth factor pathway-targeted therapies, hypertension and hand-foot syndrome (HFS) have been observed as major adverse events of anlotinib. The goal of our study was to assess if hypertension and hand-foot syndrome induced during treatment with anlotinib were associated with clinical outcome in aSTS patients treated with anlotinib.

Methods

We conducted a review of patients enrolled in ALTER0203. Median PFS was analysed in patients with hypertension and HFS vs patients with no hypertension and HFS. All analyses were exploratory and required cautious interpretation.

Results

A total of 158 patients received anlotinib in the ALTER0203 study. During the study, hypertension was observed in 99 patients (62.66%). HFS was observed in 76 patients (48.1%). Median PFS was longer in patients with hypertension vs patients with no hypertension (7.00 vs 4.37 months, p = 0.36). Patients with any grade hypertension while on anlotinib had an adjusted hazard ratio for progression of 0.81 compared to those without hypertension. Also, median PFS was longer in patients with HFS vs patients with no HFS (9.83 vs 4.3 months, p < 0.01). Patients with any grade HFS while on anlotinib had an adjusted hazard ratio for progression of 0.47 compared to those without hypertension.

Conclusions

Our data indicate that HFS may represent an interesting prognostic factor for clinical outcome in aSTS patients receiving anlotinib. There is a trend that mPFS of patients with hypertension is longer than those with no hypertension.

Clinical trial identification

NCT02449343.

Legal entity responsible for the study

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Funding

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.